PTPN6 and colorectal carcinoma: Therefore, we clarify whether the sorafenib analog regorafenib (Fluoro-sorafenib) acts as a direct enhancer of SHP-1 by which enhanced SHP-1 activity directly downregulates p-STAT3Tyr705 and eventually contributes to apoptosis in CRC.